Puma Biotechnology

Earnings Call Commercial Update



February 20, 2020






Copyright 2020 Puma Biotechnology

Forward-Looking Safe Harbor Statement

This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX[®]. All statements other than historical facts are forward–looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. ("Puma"). Forward–looking statements involve risks and uncertainties that could cause Puma's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risks and uncertainties are identified in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including, once filed, Puma's Annual Report on Form 10-K for the year ended December 31, 2019. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma's views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.




Puma's Pharmacy and Distributor Network






\$58.7 Million Net Revenue in Q4 2019





~29% of Patients in Q4 Started NERLYNX at a Reduced Dose

PERCENT OF PATIENT STARTS AT REDUCED DOSE




• Reduced Dose defined as fewer than 6 pills per day; On-Label Patients Only



Bottles Sold By Quarter





• SP = Specialty Pharmacy Network, SD = Specialty Distributor Network; Bottles defined as 180 Pills



Rest of World Partnerships – Timelines

Region	Partner	Expected Regulatory Approval
Australia / SE Asia	Specialised * Therapeutics	 March 2019 – Approved in Australia December 2019 Approved in Singapore
Israel		• Q1 2020
Canada	i Knight	 July 2019 – Approved
Greater China	CP□bridge 北海康成	 November 2019 – Approved in Hong Kong 1H 2020 – China 1H 2020 – Taiwan
Latin America South America	S PINT PHARMA	 September 2019 – Approved in Argentina 1H 2020 – Chile, Peru 2H 2020 – Mexico 2H 2020 – Colombia, Brazil, Ecuador
Europe	S Pierre Fabre	 Launch Timelines Q4 2019 – Germany-Launched Q4 2019 – United Kingdom-Launched Q4 2019 – Austria-Launched 2020-2022 – Rest of Europe

Biotechnology

Puma

Puma Biotechnology

Earnings Call Commercial Update



February 20, 2020

nerlynx[®] (neratinib) tablets



Copyright 2020 Puma Biotechnology